Anthrax Pipeline Review, H1 2019 – Therapeutic Assessment of 22 Companies & Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anthrax
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Anthrax – Pipeline Review, H1 2019, provides comprehensive information
on the therapeutics under development for Anthrax (Infectious Disease),
complete with analysis by stage of development, drug target, mechanism
of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and press
releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key
players involved in therapeutic development for Anthrax and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase II, Phase I, Preclinical, Discovery and
Unknown stages are 3, 5, 19, 6 and 1 respectively. Similarly, the
Universities portfolio in Preclinical and Discovery stages comprises 3
and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Anthrax (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Anthrax
  (Infectious Disease) by companies and universities/research institutes
  based on information derived from company and industry-specific
  sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Anthrax
  (Infectious Disease) therapeutics and enlists all their major and
  minor projects.
• The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics
  based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Anthrax (Infectious Disease)

Key Topics Covered:

1. Introduction
2. Anthrax – Overview
3. Anthrax – Therapeutics Development
4. Anthrax – Therapeutics Assessment
5. Anthrax – Companies Involved in Therapeutics Development
6. Anthrax – Drug Profiles
7. Anthrax – Dormant Projects
8. Anthrax – Discontinued Products
9. Anthrax – Product Development Milestones
10. Appendix

Companies Mentioned

• Altimmune Inc
• Aphios Corp
• Aradigm Corp
• BlueWillow Biologics Inc
• Companhia Industrial Produtora de Antibioticos SA
• Crestone Inc
• Dynavax Technologies Corp
• Elusys Therapeutics Inc
• Emergent BioSolutions Inc
• GC Pharma
• Greffex Inc
• Hawaii Biotech Inc
• iBio Inc
• Integrated BioTherapeutics Inc
• iNtRON Biotechnology Inc
• Pfenex Inc
• Protein Potential LLC
• ProThera Biologics Inc
• Q BioMed Inc
• Soligenix Inc
• Tetraphase Pharmaceuticals Inc
• VLP Biotech Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/td87t7/anthrax_pipeline?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs